Posters - NCDEU: An Annual Meeting Sponsored by ASCP

78
Posters
49. Paliperidone Palmitate (PP) for Maintenance Treatment of
Schizoaffective Disorder (SCA): Baseline Data
Dong-Jing Fu, Janssen Scientific Affairs, LLC
Ibrahim Turkoz, Richard Simonson, David Walling, Nina Schooler,
Jean-Pierre Lindenmayer, Larry Alphs
50. Patterns of Medication Adherence and Resource Utilization
Among Patients with Schizoaffective Disorder (SCA)
Michael Markowitz, Janssen Scientific Affairs, LLC
Sudeep Karve, Dong-Jing Fu, Jean-Pierre Lindenmayer, Chi-Chuan
Wang, Sean Candrilli, Larry Alphs
51. The Incidence of Tardive Dyskinesia in the Study of
Pharmacotherapy for Psychotic Depression (STOP-PD)
Daniel Blumberger, Centre for Addiction and Mental Health
Benoit Mulsant, Dora Kanellopoulos, Ellen Whyte, Anthony Rothschild,
Alastair Flint, Barnett Meyers
52. Development of a Rule Switching Test Designed to Assess
Executive Control
Keith Wesnes, Bracket, Swinburne University
Chris Edgar, Richard Wojciak, Howard Hassman, Maria Pinho, David
Kreftez, Daniel Gruener, Lawrence Brownstein, Jean Dries
53. Convergent Functional Genomics of Schizophrenia: From
Comprehensive Understanding to Genetic Risk Prediction
Alexander Niculescu, Indiana University School of Medicine
54. RP 5063 Safety, Pharmacokinetics (PK) and Pharmacodynamics
(PD) in Schizophrenia
Marc Cantillon, Reviva
Sarath Kanekal, Mike Li, Grace Li, Robert Ings, Kouacou Adiey,
Laxminaran Bhat
55. Cognitive Effects of Mecamylamine and Varenicline on
Schizophrenia
Sungwon Roh, Center for Addiction Medicine, Massachusetts General
Hospital
Luke Stoeckel, A. Eden Evins
56. Comparison of Outcomes in Patients with Early Phase versus
Later Phase Schizophrenia
Peter Feldman, Lilly Research Laboratories
Holland Detke, Christoph Correll, Chunxu Liu, John Landry, David
McDonnell
= New Investigator Q Pharmaceutical Pipeline